Ardigen enters into research collaboration with CVC to apply Artificial Intelligence for identification of T-cell targets – press release

Topic:

KRAKÓW, Poland and Auckland, New Zealand, Jul. 9, 2020 /PRNewswire/ — Ardigen and CVC announced that they entered a research collaboration aimed at the development of SARS-CoV-2 vaccine.

 

Ardigen’s neoantigen prediction platform called ‘ArdImmune Vax’ employs state of the art bioinformatics and Artificial Intelligence to identify an optimal set of neoantigens as targets for cancer vaccines or adoptive cell therapies. This technology is also very well suited for the design of vaccines for infectious diseases. The core of the platform is a proprietary algorithm capable of predicting neoantigens’ probability to elicit an immune response.

 

This joint research enables CVC to benefit from Ardigen’s vaccine design technology by selecting which viral epitopes are the most suitable to boost cellular immune response. Complementing humoral and cellular response in the vaccine design is expected to result in 2 strong lines of defense against the coronavirus. The approach is likely to be more effective than vaccines designed to create antibodies alone.

 

“We are thrilled to help global efforts to mitigate COVID-19 applying our breakthrough technology powered by Artificial Intelligence, reducing the vaccine design phase to a few weeks.” – Comments Janusz Homa, CEO of Ardigen.

 

Robert Feldman, CEO and Co-founder of CVC, adds: “CVC is excited to be working with Ardigen who are at the forefront of T-cell epitope design. The collaboration gives us the best chance of our product inducing an effective T-cell response against SARS-Cov-2”.

You might be also interested in:

banner that introduces blog post a key take aways from the Drug Discovery Conference
Data dreams and drug design: What we learned at Discovery and Development Europe 2025
BIO Convention 2025
BIO International Convention 2025 – New Standards in Collaboration, Innovation, and the Integration of AI in Biotechnology
Biologics 2.0 – From monoclonal antibodies to multispecific therapeutics
Computer Vision Meets Life Sciences: Inside the CVPR 2025 Workshop Co-Organized by Ardigen

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!